Search

Your search keyword '"Advaxis Inc. -- Intellectual property"' showing total 6 results
Start Over Descriptor "Advaxis Inc. -- Intellectual property" Journal cancer vaccine week
6 results on '"Advaxis Inc. -- Intellectual property"'

1. European Patent Office Allows Advaxis/U. Penn Modified LLO Patent

Subjects
Advaxis Inc. -- Intellectual property, Communicable diseases, Biological products, Biotechnology industry -- Intellectual property, Antigens, Patents, Proteins, Patent/copyright issue, Pharmaceuticals and cosmetics industries, Health, Science and technology, University of Pennsylvania
Abstract

Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, has been notified by the European Patent Office that patent application WO2001/072329, for the use of Prokaryotic PEST-Like [...]

Published
2010

2. Advaxis Issued New Intellectual Property Patent

Subjects
Advaxis Inc. -- Intellectual property, Intellectual property, Biotechnology industry -- Intellectual property, Drugs, Antigens, Cancer -- Care and treatment, Intellectual property, Pharmaceuticals and cosmetics industries, Health, Science and technology, University of Pennsylvania
Abstract

The U.S. Patent and Trademark Office (USPTO) issued today patent 7,635,479, 'Compositions and Methods for Enhancing the Immunogenicity of Antigens,' by Dr. Yvonne Paterson, et al, which is assigned to [...]

Published
2010

3. Advaxis Granted New Compositions and Methods Patent

Subjects
Advaxis Inc. -- Intellectual property, Biological products industry -- Intellectual property -- Methods, Communicable diseases -- Methods, Biotechnology industry -- Intellectual property -- Methods, Immunotherapy -- Methods, Antigens -- Methods, Cancer -- Care and treatment, Patents -- Methods, Patent/copyright issue, Pharmaceuticals and cosmetics industries, Health, Science and technology
Abstract

The United States Patent and Trademark Office (USPTO) has granted and issued Advaxis, Inc. (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) vaccine company, patent 7,588,930 'Compositions and Methods for [...]

Published
2009

4. Advaxis Receives US Patent and Trademark Office Approval on Act-A Protein Patent-Pending Rights

Subjects
Advaxis Inc. -- Intellectual property, Trademarks, Biotechnology industry -- Intellectual property, Antigens, Cancer -- Care and treatment, Clinical trials, Patents, Proteins, Patent/copyright issue, Pharmaceuticals and cosmetics industries, Health, Science and technology
Abstract

The US Patent and Trademark office approved Advaxis Incorporated (OTCBB: ADXS) patent-application Compositions and Methods for Enhancing the Immunogenicity of Antigens (Application # US2005/0118184 A1). This patent application covers the [...]

Published
2009

5. New Intellectual Property Patent for Advaxis Issued

Subjects
Advaxis Inc. -- Intellectual property, Intellectual property, Biotechnology industry -- Intellectual property, Cancer -- Care and treatment, Intellectual property, Pharmaceuticals and cosmetics industries, Health, Science and technology, University of Pennsylvania -- Intellectual property
Abstract

The U.S. Patent and Trademark Office (USPTO) issued today patent 7,488,487 oMethods of Inducing Immune Response Through the Administration of Auxotrophic Attenuated DAL/DAT Double Mutant Listeria Strains,o by Dr. Fred [...]

Published
2009

6. Advaxis Prevails in European Patent Court

Subjects
Advaxis Inc. -- Intellectual property, Biotechnology industry -- Intellectual property, Antigens, Cancer -- Care and treatment, Patents, Patent/copyright issue, Pharmaceuticals and cosmetics industries, Health, Science and technology
Abstract

The European Patent Court in Munich, Germany has ruled in favor of Advaxis Incorporated (OTCBB: ADXS) and reversed a patent challenge made by Anza Therapeutics, Inc., formerly Cerus Corp (NASDAQ: [...]

Published
2009

Catalog

Books, media, physical & digital resources
See catalog results